leadf
logo-loader
viewKintara Therapeutics

DelMar Pharmaceuticals talks through Phase 2 data published in peer-reviewed journal 'Glioma'

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) President & CEO Saiid Zarrabian sat down with Proactive's Christine Corrado at BIO CEO in New York. The San Diego, California-based company is focused on developing new therapies for cancer patients. Its current pipeline is based around VAL-083, a small-molecule chemotherapeutic that has demonstrated clinical activity against a range of cancers.

Quick facts: Kintara Therapeutics

Price: 1.98 USD

NASDAQ:KTRA
Market: NASDAQ
Market Cap: $60.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

KRM22 says new partnership with Kintail Consulting 'brings together...

KRM22 PLC's (LON:KRM) Keith Todd caught up with Proactive London to discuss their new partnership with consultancy and strategy services firm Kintail Consulting to address the area of people and culture risk in capital markets. Todd explains that after the 2008 crisis, regulators made clear...

15 hours, 12 minutes ago

2 min read